Morgan Stanley (NYSE:MS) analyst Ricky Goldwasser maintained a Sell rating on NextGen Healthcare (NASDAQ:NXGN) Inc on Monday, setting a price target of $14, which is approximately 6.73% below the present share price of $15.01.
Goldwasser expects NextGen Healthcare Inc to post earnings per share (EPS) of $0.16 for the fourth quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Hold rating of shares in NextGen Healthcare, with an average price target of $15.13.
The analysts price targets range from a high of $21 to a low of $13.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $140 million and a net profit of $10.3 million. The company's market cap is $1 billion.
According to TipRanks.com, Morgan Stanley analyst Ricky Goldwasser is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.9% and a 67.02% success rate.
NextGen Healthcare, Inc. engages in the development and marketing of electronic health records, practice management, revenue cycle management, and interoperability solutions. It offers the core; automation and workflow; analytics, population health, and patient engagement, interoperability; managed services; professional services; and client service and support. The company was founded by Sheldon Razin in 1974 and is headquartered in Irvine, CA.